{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:22:53Z","timestamp":1778620973400,"version":"3.51.4"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":219,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p><jats:italic>Objective<\/jats:italic>. To evaluate efficacy and adverse events of ceftolozane\/tazobactam in complicated UTI including acute pyelonephritis. <jats:italic>Method<\/jats:italic>. Databases that include PubMed, Embase, Scopus, and TRIP were searched. All randomized controlled trials and cohort studies were considered for the study. Statistical analysis was done using a fixed effects model, and results were expressed in proportion for dichotomous data and risk ratio for continuous data with 95% confidence intervals (CI). <jats:italic>Results<\/jats:italic>. A clinical cure of ceftolozane\/tazobactam was found to be 92% with 95% CI of 90\u201094 while that of piperacillin\/tazobactam was only 78% (95% CI, 74\u201082) in patients with complicated UTI. Microbiological eradication was still higher in the ceftolozane\/tazobactam group (83%, 95% CI 81\u201088) when compared with piperacillin\/tazobactam (63% 95% CI, 58.77\u201065.2). Ceftolozane\/tazobactam was more effective in the treatment of complicated urinary tract infections other than acute pyelonephritis as compared to piperacillin\/tazobactam (RR = 1.21, 95% CI, 1.07\u20101.23). Serious adverse events were found comparable in both groups (RR = 1.15, 95% CI, 0.64\u20102.09). <jats:italic>Conclusion<\/jats:italic>. The analysis showed that ceftolozane\/tazobactam has better clinical outcomes including cure rates and low resistance for the treatment of complicated urinary tract infection.<\/jats:p>","DOI":"10.1155\/2022\/1639114","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T05:50:15Z","timestamp":1660024215000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Meta\u2010Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections"],"prefix":"10.1155","volume":"2022","author":[{"given":"Muhammad Waqas","family":"Saeed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-2068","authenticated-orcid":false,"given":"Syed Wasif","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9569-7888","authenticated-orcid":false,"given":"Rana Kamran","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanna","family":"Vippadapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mian Waqar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassaan Anwer","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq298"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/427507"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/385768"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2007.09.010"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-008-0652-X"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.11.1136"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir109"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01704364"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05929-3"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir102"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363170-00006"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_2_9_13_2","unstructured":"Urinary Tract Infections- ClinicalKey 2020 https:\/\/www.clinicalkey.com\/#!\/content\/book\/3-s2.0-B9781437701265000392?scrollTo=%23hl0000106 \/."},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018769"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01133-08"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085611"},{"key":"e_1_2_9_17_2","first-page":"350","article-title":"Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient","volume":"5","author":"Eden G.","year":"2012","journal-title":"Nephrology Dialysis Transplantation Plus"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.02.002"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx009"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.04.004"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.4137\/PMC.S14459"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.2.462"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614554919"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898http:\/\/www.bmj.com\/"},{"key":"e_1_2_9_27_2","unstructured":"Study Quality Assessment Tools | NHLBI NIH 2021."},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1996.8.2.122"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz181"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.10.009"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2502-x"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa139"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.07.003"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01587-18"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1178633720905977"},{"key":"e_1_2_9_38_2","article-title":"Critical evaluation of ceftolozane\u2013tazobactam for complicated urinary tract and intra-abdominal infections","volume":"12","author":"Giancola S. E.","year":"2016","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.11.015"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix034"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-10"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.4274\/mjima.galenos.2020.2020.11"},{"key":"e_1_2_9_44_2","article-title":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications- ClinicalKey","volume":"55","author":"Maraolo A. E.","year":"2021","journal-title":"International Journal of Antimicrobial Agents"}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2022\/1639114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2022\/1639114.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/1639114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:50:24Z","timestamp":1735631424000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/1639114"}},"subtitle":[],"editor":[{"given":"Oguz R.","family":"Sipahi","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/1639114"],"URL":"https:\/\/doi.org\/10.1155\/2022\/1639114","archive":["Portico"],"relation":{},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"value":"2314-6133","type":"print"},{"value":"2314-6141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1639114"}}